Moderna, Inc. has rallied ~23%, but rated a Sell due to deteriorating fundamentals. Learn more about MRNA stock here.

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 4% in the morning session after the company ...

After donating $176 million in proceeds from his original stock options in 2023, Stéphane Bancel is taking a different path ...

Moderna announced Thursday it will receive up to $54.3 million from a global vaccine partnership to fund its ongoing research ...

As support from the U.S. government has evaporated, Moderna is leaning on an old ally to carry plans for its prospective mRNA ...

Moderna has tapped Swedish long-acting drug formulation company Nanexa to improve the delivery of up to five injectable ...

Moderna will get up to $54.3 million in funding from a global coalition to support late-stage development of its experimental ...

Momentum traders who seek fast-moving stocks have three to look at. Sandisk (SNDK) gained 15.2% in the last week. It trades ...

Since that moment, Moderna has taken steps to pave the path to long-term growth -- from cutting costs to focusing on its vast pipeline. Considering the full picture, now, with the stock down 80% over ...

Up to $54.3 million CEPI investment aims to help advance Moderna’s H5 pandemic influenza vaccine candidate to licensure Partnership strengthens global preparedness against a significant pandemic ...

Moderna Inc. will get as much as $54.3 million for a late-stage trial of its bird flu vaccine in a sign of how outside groups ...

Stéphane Bancel, Moderna’s founding chief executive, has sold his six-level Beacon Hill townhouse after owning in the ...